Discontinued — last reported Q1 '26
Products & Services · Sales
Keytruda Qlex — Sales
This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market demand and successful commercial execution, while a decrease may signal competitive pressure or market saturation.
Detailed definition
This represents the total revenue generated from the sale of a specific product line or therapeutic asset within a given...
Peer comparison
Standard revenue reporting metric for all public companies, specifically used in pharma to track individual drug performance.
Metric ID:
mrk_segment_keytruda_qlex_salesHistorical Data
10 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $128.00M |
Range$0.00 – $128.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s keytruda qlex — sales?
- Merck & Co. (MRK) reported keytruda qlex — sales of $128.00M in Q1 2026.
- What does keytruda qlex — sales mean?
- The total revenue earned from selling this specific product.